MS Pharma Group has entered into a strategic partnership with Hetero Group to localize five established biosimilars across key therapeutic areas, including oncology, immunology, and hematology.
Key highlights:
-
Target market: The agreement will be implemented via El Kendi (MS Pharma’s affiliate in Algeria) and Hetero Biopharma. This marks Hetero’s first localized biopharmaceutical venture in Algeria.
-
Economic value: The combined portfolio represents an estimated market value of $45 million in Algeria.
-
Implementation method: The project will follow a localization and technology transfer approach, significantly strengthening Algeria’s biopharmaceutical ecosystem.
Strategic vision:
Kalle Känd, CEO of MS Pharma, highlighted that the collaboration aims to expand patient access to affordable, high-quality biologic treatments while enhancing the resilience of local healthcare systems. Dr. Vamsi Krishna, MD of Hetero Group, stated that this partnership is a vital step toward addressing unmet medical needs across Algeria and the broader Middle East markets.